Sinovac Biotech (SVA) Tops Q4 EPS by 1c

Sinovac Biotech (NASDAQ: SVA) reported Q4 EPS of $0.02, $0.01 better than the analyst estimate of $0.01. Revenue for the quarter came in at $22.9 million versus the consensus estimate of $14.1 million.

For earnings history and earnings-related data on Sinovac Biotech (SVA) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Innovaro (INV) Misses Q2 EPS by 9c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c